Should I Buy LMAT? LMAT 2026 Analysis

Should You Buy LeMaitre Vascular Inc (LMAT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

84.970

1 Day change

1.32%

52 Week Range

105.550

Analysis Updated At

2026/01/30

BUY now. LMAT is sitting right on key support (~83.83) after a mild pullback, while fundamentals (Q3 growth and margin expansion) and the lone recent Street view (Buy, $108 PT) remain clearly positive. There’s no fresh negative news flow, and upcoming product/regulatory catalysts plus the next earnings date (2026-02-23) create a near-term catalyst window that supports buying at current levels for an impatient investor.

Technical Analysis

Trend/momentum is short-term bearish but approaching an actionable support area. MACD histogram (-0.0717) is below zero and expanding negatively, signaling weakening momentum. RSI(6) at ~38.5 is weak (near oversold territory), often consistent with late-stage pullbacks rather than fresh breakdowns. Price closed ~83.82, essentially at S1 (83.833) and below the pivot (85.785), making the immediate setup a support-retest: if it holds, the next upside levels are the pivot (~85.79) then R1 (~87.74). Moving averages are converging, implying consolidation rather than a strong downtrend. Pattern-based projection provided: ~80% chance of a small down day next session (-0.4%), but a stronger 1-week upside bias (+10.39%), which fits a ‘support then bounce’ setup. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Options positioning is mixed but leans toward longer-horizon bullish positioning with short-term caution. Open Interest Put-Call Ratio at 0.45 indicates more call OI than put OI (constructively bullish). However, the Option Volume Put-Call Ratio at 3.0 shows today’s activity skewed to puts (near-term defensive/hedging tone), though absolute volumes are small (total volume 8). Implied volatility (30d) is elevated (61.5) versus historical volatility (~20), suggesting options are pricing meaningful moves; IV percentile is low (8.8), implying IV is low relative to its own recent distribution even if high versus realized—overall: sentiment is not euphoric, but the market is paying up for protection/optional exposure ahead of catalysts/earnings.

Technical Summary

Sell

Buy

Positive Catalysts

Strong recent operating performance (Q3: double-digit revenue growth and major earnings leverage).
Analyst catalyst roadmap: RestoreFlow approvals in Ireland and Germany; XenoSure vascular patch regulatory submission in China.
Next earnings on 2026-02-23 (after hours) can act as a catalyst if growth/margins persist.
Technically, price is at a defined support level (S1 ~83.83), which can attract dip-buyers if it holds.

Neutral/Negative Catalysts

Near-term technical momentum is bearish (MACD worsening) and price is below the pivot, so the tape can stay heavy before any rebound.
Hedge funds are selling (selling amount up ~398% over the last quarter), a sentiment headwind.
Options volume skewed to puts today (volume P/C 3.0), indicating short-term caution/hedging.
No supportive recent news in the last week to immediately reverse momentum.

Financial Performance

Latest quarter: 2025/Q3. Revenue grew to ~$61.0M (+11.36% YoY). Net income rose to ~$17.36M (+55.84% YoY) and EPS to $0.71 (+44.90% YoY), showing strong operating leverage. Gross margin improved to ~75.28 (up ~11% YoY), reinforcing quality of growth and profitability momentum.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent Street activity is positive but limited: Roth Capital (2025-11-05) resumed coverage with a Buy and a $108 price target, citing ~15% organic sales growth, benefits from a 164-rep direct sales force, and upcoming regulatory/product catalysts. Wall Street ‘pros’ case: strong organic growth, margin expansion, and catalyst pipeline. ‘Cons’ case (from the provided data): institutional/hedge fund selling pressure and currently weak technical momentum. No recent politician/congress trading data was available; insiders are neutral with no significant recent trend.

7 Analyst Rating

Wall Street analysts forecast LMAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LMAT is 105.2 USD with a low forecast of 93 USD and a high forecast of 120 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 83.860

Low

Averages

105.2

High

120

Current: 83.860

Low

Averages

105.2

High

120

Roth Capital

initiated

$108

AI Analysis

2025-11-05

Reason

Roth Capital

Price Target

$108

AI Analysis

2025-11-05

initiated

Reason

Roth Capital resumed coverage of LeMaitre with a Buy rating and $108 price target. The firm says the company's product portfolio vascular surgeons combined with its direct sales force of 164 reps is driving organic sales growth of 15% with favorable operating leverage. It sees upcoming catalysts for LeMaitre from RestoreFlow approvals in Ireland and Germany as well as the XenoSure vascular patch regulatory submission in China.

Barrington

Michael Petusky

Market Perform

Outperform

upgrade

$95

2025-08-06

Reason

Barrington

Michael Petusky

Price Target

$95

2025-08-06

upgrade

Market Perform

Outperform

Reason

Barrington analyst Michael Petusky upgraded LeMaitre to Outperform from Market Perform with a $95 price target. The company reported strong Q2 results with 15% organic growth and 25% operating margins, the analyst tells investors in a research note. The firm now has conviction that LeMaitre will have a good second half of 2025 and even better 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LMAT

Unlock Now

LMAT Should I Buy

LMAT Should I Buy

Should You Buy LeMaitre Vascular Inc (LMAT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch